Cigna Group

Cigna Group (CI) (Q3FY24) – Strategic resilience and market challenges

Highlights of the report

The Medicare Advantage market is facing challenges due to factors like elevated medical costs, changes in SARS ratings, and a reset of risk-adjusted revenue streams, leading to operational disruption for some.

Cigna Group (CI) Equity Report Q3FY24

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.

 

CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).

 

Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States.

Cigna Group’s revenue has increased by 30% to $63.69bn in Q3FY24 from $49.04bn in Q3FY23, COGS as % of sales has increased to 90% in Q3FY24 from 87% in Q3FY23.

Over the last 3 months Cigna Group stock dropped by (8.74%), where the stock declined from $353.49 as of 06th Sep 2024 to $322.61 as of 05th Dec 2024.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

Report details

Cigna Group (CI) (Q3FY24) – Strategic resilience and market challenges

Price

$288.00

Company Reports

Sector Reports